دورية أكاديمية

Impact of type of oral anticoagulants in patients with cerebral microbleeds after atrial fibrillation-related ischemic stroke or TIA: Results of the NOACISP-LONGTERM registry

التفاصيل البيبلوغرافية
العنوان: Impact of type of oral anticoagulants in patients with cerebral microbleeds after atrial fibrillation-related ischemic stroke or TIA: Results of the NOACISP-LONGTERM registry
المؤلفون: Benjamin Wagner, Lisa Hert, Alexandros A. Polymeris, Sabine Schaedelin, Johanna M. Lieb, David J. Seiffge, Christopher Traenka, Sebastian Thilemann, Joachim Fladt, Valerian L. Altersberger, Annaelle Zietz, Tolga D. Dittrich, Urs Fisch, Henrik Gensicke, Gian Marco De Marchis, Leo H. Bonati, Philippe A. Lyrer, Stefan T. Engelter, Nils Peters
المصدر: Frontiers in Neurology, Vol 13 (2022)
بيانات النشر: Frontiers Media S.A., 2022.
سنة النشر: 2022
المجموعة: LCC:Neurology. Diseases of the nervous system
مصطلحات موضوعية: stroke, atrial fibrillation, anticoagulation, direct-acting oral anticoagulant, cerebral microbleeds, small vessel disease, Neurology. Diseases of the nervous system, RC346-429
الوصف: BackgroundCerebral microbleeds (CMBs) may have a differential impact on clinical outcome in stroke patients with atrial fibrillation (AF) treated with different types of oral anticoagulation (OAC).MethodsObservational single-center study on AF-stroke-patients treated with OAC. Magnetic-resonance-imaging was performed to assess CMBs. Outcome measures consisted of recurrent ischemic stroke (IS), intracranial hemorrhage (ICH), death, and their combined analysis. Functional disability was assessed by mRS. Using adjusted logistic regression and Cox proportional-hazards models, we assessed the association of the presence of CMBs and OAC type (vitamin K antagonists [VKAs] vs. direct oral anticoagulants [DOACs]) with clinical outcome.ResultsOf 310 AF-stroke patients treated with OAC [DOACs: n = 234 (75%); VKAs: n = 76 (25%)], CMBs were present in 86 (28%) patients; of these, 66 (77%) received DOACs. In both groups, CMBs were associated with an increased risk for the composite outcome: VKAs: HR 3.654 [1.614; 8.277]; p = 0.002; DOACs: HR 2.230 [1.233; 4.034]; p = 0.008. Patients with CMBs had ~50% higher absolute rates of the composite outcome compared to the overall cohort, with a comparable ratio between treatment groups [VKAs 13/20(65%) vs. DOACs 19/66(29%); p < 0.01]. The VKA-group had a 2-fold higher IS [VKAs:4 (20%) vs. DOACs:6 (9%); p = 0.35] and a 10-fold higher ICH rate [VKAs: 3 (15%) vs. DOACs: 1 (1.5%); p = 0.038]. No significant interaction was observed between type of OAC and presence of CMBs. DOAC-patients showed a significantly better functional outcome (OR 0.40 [0.17; 0.94]; p = 0.04).ConclusionsIn AF-stroke patients treated with OAC, the presence of CMBs was associated with an unfavorable composite outcome for both VKAs and DOACs, with a higher risk for recurrent IS than for ICH. Strokes were numerically higher under VKAs and increased in the presence of CMBs.Clinical trial registrationhttp://www.clinicaltrials.gov, Unique identifier: NCT03826927.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1664-2295
Relation: https://www.frontiersin.org/articles/10.3389/fneur.2022.964723/full; https://doaj.org/toc/1664-2295
DOI: 10.3389/fneur.2022.964723
URL الوصول: https://doaj.org/article/5116b2ca04544fe89ea82f88d4e3ec99
رقم الأكسشن: edsdoj.5116b2ca04544fe89ea82f88d4e3ec99
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:16642295
DOI:10.3389/fneur.2022.964723